Patients were divided into two groups based on ADAMTS1 or HSPG2 expression levels higher or lower than the median value (low and high), to analyze the relationship between ADAMTS1 or HSPG2 expression and COH outcomes. The gene discussed is HSPG2; the disease is Cohen syndrome.